Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial.
Journal: Journal of the American College of Cardiology
Published: February 13, 2026
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label Trial.
Journal: Journal of the American College of Cardiology
Published: September 04, 2025
Patient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker Correlations.
Journal: JACC. Advances
Published: December 11, 2023
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.
Journal: JAMA cardiology
Published: January 18, 2023
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
Journal: Journal of the American College of Cardiology
Published: April 01, 2022
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Journal: European journal of heart failure
Published: March 29, 2022
The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: February 24, 2022
Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Journal: Journal of medical economics
Published: September 08, 2021
Assessment of Disease Status and Treatment Response With Artificial Intelligence-Enhanced Electrocardiography in Obstructive Hypertrophic Cardiomyopathy.
Journal: Journal of the American College of Cardiology
Published: July 19, 2021
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Journal: American heart journal
Published: March 18, 2021
Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies.
Journal: Journal of the American Heart Association
Published: July 29, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: July 22, 2020
Last Updated: 09/26/2026